Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$3.07 USD
-0.17 (-5.25%)
Updated May 10, 2024 04:00 PM ET
After-Market: $3.07 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Brokerage Reports
Cellectar Biosciences, Inc. [CLRB]
Reports for Purchase
Showing records 61 - 80 ( 120 total )
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Expands Existing Drug Linker/Payload Collaboration with IntoCell
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Signs Drug Development/Commercialization Collaboration with LegoChem Bio
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Positive Clinical Update From CLOVER-1 Bodes Well For CLOVER-WaM
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Phase 2a Results Show Consistent CLR 131 Efficacy in Refractory LPL/WM
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
WM Pivotal Study Advancing; IP Strengthened; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
1Q21: Pivotal WM Trial Results Likely in 3Q22, Well-Funded for Two Years
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Strengthens PDC Technology IP Estate; CLR 131 Pivotal Trial Progressing
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Healthcare- Annual ROTH Conference: Cancer Panel Takeaways
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Pivotal Study in WM Initiated; Clinical Updates in 2021 Could Provide Inflection; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
4Q20; Well-Funded into Mid-2023 & Enrolling Pivotal CLR 131 Trial in WM
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Biotechnology: Invitation: Virtual 33rd Annual Roth Conference (March 15-17)
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Pivotal Study on Deck for 4Q20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
3Q20: Looking Forward to Pivotal Trial Initiation for CLR 131 in LPL/WM
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J